vs

Side-by-side financial comparison of APOGEE ENTERPRISES, INC. (APOG) and CLOVER HEALTH INVESTMENTS, CORP. (CLOV). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $351.4M, roughly 1.4× APOGEE ENTERPRISES, INC.). APOGEE ENTERPRISES, INC. runs the higher net margin — 4.7% vs -10.1%, a 14.8% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 1.6%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 2.9%).

Apogee Electronics is an American manufacturer of audio interfaces, analog-to-digital and digital-to-analog converters, USB & iOS microphones, and audio production software.

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

APOG vs CLOV — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.4× larger
CLOV
$487.7M
$351.4M
APOG
Growing faster (revenue YoY)
CLOV
CLOV
+43.1% gap
CLOV
44.7%
1.6%
APOG
Higher net margin
APOG
APOG
14.8% more per $
APOG
4.7%
-10.1%
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
2.9%
APOG

Income Statement — Q4 FY2026 vs Q4 FY2025

Metric
APOG
APOG
CLOV
CLOV
Revenue
$351.4M
$487.7M
Net Profit
$16.6M
$-49.3M
Gross Margin
22.4%
Operating Margin
7.3%
-10.1%
Net Margin
4.7%
-10.1%
Revenue YoY
1.6%
44.7%
Net Profit YoY
568.8%
-123.2%
EPS (diluted)
$0.78

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
APOG
APOG
CLOV
CLOV
Q1 26
$351.4M
Q4 25
$348.6M
$487.7M
Q3 25
$358.2M
$496.6M
Q2 25
$346.6M
$477.6M
Q1 25
$345.7M
$462.3M
Q4 24
$341.3M
$337.0M
Q3 24
$342.4M
$331.0M
Q2 24
$331.5M
$356.3M
Net Profit
APOG
APOG
CLOV
CLOV
Q1 26
$16.6M
Q4 25
$16.5M
$-49.3M
Q3 25
$23.6M
$-24.4M
Q2 25
$-2.7M
$-10.6M
Q1 25
$2.5M
$-1.3M
Q4 24
$21.0M
$-22.1M
Q3 24
$30.6M
$-9.2M
Q2 24
$31.0M
$7.4M
Gross Margin
APOG
APOG
CLOV
CLOV
Q1 26
22.4%
Q4 25
23.8%
Q3 25
23.1%
Q2 25
21.7%
Q1 25
21.6%
Q4 24
26.1%
Q3 24
28.4%
24.5%
Q2 24
29.8%
30.3%
Operating Margin
APOG
APOG
CLOV
CLOV
Q1 26
7.3%
Q4 25
7.1%
-10.1%
Q3 25
7.5%
-4.9%
Q2 25
2.0%
-2.2%
Q1 25
1.8%
-0.3%
Q4 24
8.4%
-6.4%
Q3 24
12.3%
-2.7%
Q2 24
12.5%
2.0%
Net Margin
APOG
APOG
CLOV
CLOV
Q1 26
4.7%
Q4 25
4.7%
-10.1%
Q3 25
6.6%
-4.9%
Q2 25
-0.8%
-2.2%
Q1 25
0.7%
-0.3%
Q4 24
6.1%
-6.6%
Q3 24
8.9%
-2.8%
Q2 24
9.4%
2.1%
EPS (diluted)
APOG
APOG
CLOV
CLOV
Q1 26
$0.78
Q4 25
$0.77
Q3 25
$1.10
Q2 25
$-0.13
Q1 25
$0.12
Q4 24
$0.96
Q3 24
$1.40
Q2 24
$1.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
APOG
APOG
CLOV
CLOV
Cash + ST InvestmentsLiquidity on hand
$39.5M
$78.3M
Total DebtLower is stronger
$232.3M
Stockholders' EquityBook value
$511.8M
$308.7M
Total Assets
$1.1B
$541.0M
Debt / EquityLower = less leverage
0.45×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
APOG
APOG
CLOV
CLOV
Q1 26
$39.5M
Q4 25
$41.3M
$78.3M
Q3 25
$39.5M
Q2 25
$32.8M
Q1 25
$41.4M
Q4 24
$43.9M
$194.5M
Q3 24
$51.0M
$288.0M
Q2 24
$30.4M
$254.8M
Total Debt
APOG
APOG
CLOV
CLOV
Q1 26
$232.3M
Q4 25
Q3 25
Q2 25
Q1 25
$285.0M
Q4 24
Q3 24
Q2 24
Stockholders' Equity
APOG
APOG
CLOV
CLOV
Q1 26
$511.8M
Q4 25
$512.3M
$308.7M
Q3 25
$500.2M
$340.9M
Q2 25
$481.8M
$344.2M
Q1 25
$487.9M
$336.1M
Q4 24
$522.1M
$341.1M
Q3 24
$506.4M
$342.2M
Q2 24
$480.0M
$324.9M
Total Assets
APOG
APOG
CLOV
CLOV
Q1 26
$1.1B
Q4 25
$1.1B
$541.0M
Q3 25
$1.2B
$559.7M
Q2 25
$1.2B
$575.0M
Q1 25
$1.2B
$583.7M
Q4 24
$1.2B
$580.7M
Q3 24
$917.1M
$653.0M
Q2 24
$889.0M
$674.2M
Debt / Equity
APOG
APOG
CLOV
CLOV
Q1 26
0.45×
Q4 25
Q3 25
Q2 25
Q1 25
0.58×
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
APOG
APOG
CLOV
CLOV
Operating Cash FlowLast quarter
$122.5M
$-66.9M
Free Cash FlowOCF − Capex
$-69.0M
FCF MarginFCF / Revenue
-14.1%
Capex IntensityCapex / Revenue
7.8%
0.4%
Cash ConversionOCF / Net Profit
7.37×
TTM Free Cash FlowTrailing 4 quarters
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
APOG
APOG
CLOV
CLOV
Q1 26
$122.5M
Q4 25
$29.3M
$-66.9M
Q3 25
$57.1M
$12.1M
Q2 25
$-19.8M
$5.4M
Q1 25
$30.0M
$-16.3M
Q4 24
$31.0M
$34.8M
Q3 24
$58.7M
$50.0M
Q2 24
$5.5M
$44.8M
Free Cash Flow
APOG
APOG
CLOV
CLOV
Q1 26
Q4 25
$22.9M
$-69.0M
Q3 25
$52.4M
$11.4M
Q2 25
$-26.9M
$4.8M
Q1 25
$19.1M
$-16.5M
Q4 24
$22.0M
$33.3M
Q3 24
$50.2M
$49.6M
Q2 24
$-1.8M
$44.4M
FCF Margin
APOG
APOG
CLOV
CLOV
Q1 26
Q4 25
6.6%
-14.1%
Q3 25
14.6%
2.3%
Q2 25
-7.8%
1.0%
Q1 25
5.5%
-3.6%
Q4 24
6.4%
9.9%
Q3 24
14.7%
15.0%
Q2 24
-0.5%
12.5%
Capex Intensity
APOG
APOG
CLOV
CLOV
Q1 26
7.8%
Q4 25
1.9%
0.4%
Q3 25
1.3%
0.1%
Q2 25
2.1%
0.1%
Q1 25
3.2%
0.0%
Q4 24
2.6%
0.5%
Q3 24
2.5%
0.1%
Q2 24
2.2%
0.1%
Cash Conversion
APOG
APOG
CLOV
CLOV
Q1 26
7.37×
Q4 25
1.77×
Q3 25
2.41×
Q2 25
Q1 25
12.08×
Q4 24
1.48×
Q3 24
1.92×
Q2 24
0.18×
6.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

APOG
APOG

Architectural Services$127.1M36%
Architectural Metals$110.0M31%
Architectural Glass$67.4M19%
Performance Surfaces$54.3M15%

CLOV
CLOV

Segment breakdown not available.

Related Comparisons